Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray
September 6, 2017 10:57 AM EDT(Updated - September 6, 2017 11:00 AM EDT)
(updated to add analyst comment)
Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.
Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More
Sarepta (SRPT) SRP-4053 Data Strengthen Case for Exon Expansion Approach - Baird; Reit. OP, $101 PT
September 6, 2017 8:30 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $101 price target on Sarepta Therapeutics (NASDAQ: SRPT) following positive European Phase 1/2 study of SRP-4053.
Skorney said this strengthens the case for Sarepta's approach to exon expansion.
"With dystrophin expression exceeding that... More
